From Research to Essential Care
The Opportunities
The reduced cost of sequencing and the explosion of genomic data have shifted the field from research to precision medicine necessity
>
Declining Cost of Genome Sequencing
The human genome sequence cost decreased from an estimated $1 million in 2007 to approximately $600.
>
Rising Biobank Data
24 biobanks with different origins of ancestries have joined GBMI with >2.2 million genotyped samples
>
Evidence of Clinical Utility
Emerging initiatives globally for using genomics to prevent disease earlier in the life course
The Challenges
Bridging the Gap
Addressing the Disparity in Genomic Medicine in the Arab World
While genomic medicine is transforming health, the Arab world is lagging behind
Massive Under-Representation
Arabs account for 5% of the world population but 0.16% of genomic study participants
Rising Disease Burden
Highest rates of cardiometabolic disease globally
Missed Discovery Opportunities
Low contribution to drug discovery
Understanding the Unique Challenges
Adapting Genomic Medicine for the Arab World
Genomic medicine holds great promise, but directly applying Western models to the Arab world presents several challenges. The following factors highlight why a tailored approach is essential for effective implementation:
- Different genetic makeup and risk factor profiles
- Lower performance of genomic risk models
- Unique cultural and social factors
Understanding the Impact and Necessity of Effective Solutions
The Problem
The rising prevalence of cardiometabolic diseases and cancer in the MENA region poses a significant challenge to public health systems and places a considerable strain on healthcare expenditure.
Burden of Cardiometabolic Diseases in the MENA Region
Poses a significant challenge to public health and places considerable strain on the region's healthcare expenditures.
Public Health Initiatives
Public health initiatives, awareness campaigns, and funds allocated for preventive measures and early intervention are crucial.
Prevalence of Cardiometabolic and Cancer Diseases
The increase in the prevalence of cardiovascular diseases and cancer not only leads to an elevated morbidity and mortality rate but also requires substantial financial investment.
Avigena
Leading the New Era of Personalized Medicine
Avigena is revitalizing healthcare in the MENA region, drawing inspiration from the historical Golden Age of Medicine.
Our approach integrates cutting-edge genomic medicine with virtual care technologies to transform patient treatment and care strategies.
This innovative model not only individualizes healthcare but also propels advancements in public health and drug development. By prioritizing genomic insights as a fundamental component of healthcare delivery, Avigena is making precision medicine accessible to all, promising a healthier future for every individual in the region.
Our approach integrates cutting-edge genomic medicine with virtual care technologies to transform patient treatment and care strategies.
This innovative model not only individualizes healthcare but also propels advancements in public health and drug development. By prioritizing genomic insights as a fundamental component of healthcare delivery, Avigena is making precision medicine accessible to all, promising a healthier future for every individual in the region.
Integrating Western Innovation with Local Expertis
A Tailored Genomic Medicine Solution for the Arab World
To effectively address the challenges of common diseases in the MENA region, a genomic medicine company must combine the best of Western advancements with a deep understanding of local needs. This approach ensures that genomic medicine is both cutting-edge and culturally relevant.
Informed by the West
- Use cutting-edge technologies and the latest innovations
- Leverage existing massive non-Arab datasets
- Team with scientists at the forefront of genomic medicine
Rooted in the Arab world
- Optimize the performance of genomic medicine models for Arabs
- Provide culturally appropriate care based on a deep understanding of Arab people
- Leverage the unique genomic composition of Arabs to advance discoveries
Avigena
Global Collaboration, Localized Care "Glocalization"
Avigena boasts profound scientific expertise and operational strength, derived from its founding team and extensive global partnerships.
These assets enable us to conduct world-class research in genomic risk model development and the implementation of preventive genomics. Additionally, we are at the forefront of pioneering virtual care products in the US and international markets.
These assets enable us to conduct world-class research in genomic risk model development and the implementation of preventive genomics. Additionally, we are at the forefront of pioneering virtual care products in the US and international markets.
Innovating Genomic Medicine in the MENA Region
Our Company Traction
Avigena blends Eastern and Western medical expertise, utilizing cutting-edge science to establish a robust infrastructure tailored for the MENA region. We prioritize four essential domains to drive advancements in genomic medicine